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Dermatologists use depigmenting creams with various active ingre­
dients in the treatment of melasma and post­inflammatory hyper­
pigmentation.[1] Skin lightening or bleaching refers to the cosmetic 
practice of applying depigmenting agents not as treatment for 
hyperpigmentation but with the deliberate aim of achieving a lighter 
skin colour. It is a practice that is common in many places (e.g. India, 
Africa and America) with pigmented populations and a history of 
improved social status with lighter complexion. Adverse effects are 
associated with active ingredients (mercury, hydroquinone and potent 
steroids) in depigmenting creams and are illegal in cosmetics in many 
countries. Further illegal ingredients in Africa have been shown to be 
imported from Europe (in spite of a European Union ban).[2]
Glutathione (GSH) was first discovered by Hopkins[3[ in 1921 in 
yeasts, and subsequently in other tissues.[4] It is a tripeptide  com­
posed of L­cysteine, glycine and glutamate that is synthesised 
intra cellularly.[5,6] It is considered the main redox buffer in human 
cells owing to its large amount of reducing equivalents,[7] and is an 
impor tant enzyme cofactor that serves as a neuromodulator in the 
central nervous system. The tripeptide exists intracellularly either in 
an oxidised glutathione disulphide (GSSG) or reduced state (GSH), 
and maintaining an optimal GSH:GSSG ratio in the cell is critical 
for prevention of oxidative damage and for cell survival (Fig. 1).[8] 
An imbalance in GSH and its use as a marker of oxidative stress 
is reported in many diseases including cancer, neurodegenerative 
disorders, cystic fibrosis, HIV,[9] diabetes mellitus,[10] anorexia 
nervosa[11] and autism[12,13] and in low­birth­weight neonates.[14]
Reports of systemic skin lightening with GSH have appeared with 
increasing frequency on social media, and clinics advertise it online 
in many countries (Africa, the USA, Canada, Mexico, etc.). Our 
objective was to conduct a literature search to identify all academic 
reports of GSH use for skin lightening and all clinical trials of GSH 
use for all indications in medicine.
Methods
Two MEDLINE searches for studies published up to September 2015 
were conducted. The search terms for the first were ‘glutathione AND 
skin lightening’, and for the second ‘glutathione AND randomised 
controlled trial’. Inclusion criteria were any treatment report of 
GSH for skin lightening (or hyperpigmentation) and GSH for any 
randomised control trial (RCT) for the first and second searches, 
respectively. Abstracts were read independently by two authors to 
identify relevant articles.
Results
Nine articles were identified from the first MEDLINE search. Six 
publications mentioned GSH as part of reviews related to melanin 
(kojic acid in rats,[15] piceatannol inhibition of mushroom tyrosin­
ase,[16] oral zinc sulphate murine hair hypopigmentation,[17] hydro­
quin one occupational exposure[18] (and toxicity for skin lightening) [19] 
and natural ingredient­containing treatments for hyperpigmen­
tation.[20] A seventh article was an extensive review of biochemical 
mechanisms of how GSH causes depigmentation in cell cultures and 
laboratory animals.[21] Five clinical reports (4 published since 2012) 
of the use of GSH for skin lightening were identified (2 from the 
MEDLINE search and 3 from references). The first, a pharmacokinetic 
study of GSH in seven participants, did not measure skin lightening 
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or report side­effects.[22] A case series of 
15  patients from India treated with a GSH­
containing soap for melanosis of the face 
reported lightening (in 11/15 after 3 months) 
based on clinical photographs. However, no 
mention was made of how the conditions for 
photography were standardised or of follow­
up on stopping treatment.[23] A controlled 
trial from Thailand tested 250 mg GSH 
capsules twice daily in two groups each of 30 
medical students over 4 weeks. They repor­
ted a decreased melanin index measured at 
six body sites (but statistically significant 
only at two sites, namely the right side of 
the face (p=0.021) and the sun­exposed left 
forearm (p=0.036)).[24] Watanabe et al.[25] 
from Japan reported a significant reduction 
in the melanin index (mean (standard 
deviation), week 0: 272.77 (26.17); week 10: 
243.47 (26.31)) in subjects treated with a 
GSSG­containing lotion measured with a 
Mexameter MX18 (Courage + Khazaka Elec­
tronic GmbH, Germany). Investigators and 
participants also subjectively scored GSSG­
treated skin as lighter. The most recent 
study is an uncontrolled trial of 30  Filipino 
women. The authors reported a significant 
reduc tion in melanin index (measured with 
a portable mexameter) (p<0.0001) after 
500  mg GSH lozenges were administered 
daily for 8 weeks. [26] None of the studies 
repor ted significant adverse effects or follow­
up beyond the study period (Table 1).
Of the plethora of articles retrieved from 
the second MEDLINE search, we identi­
fied 28 systematic reviews of animal stud­
ies,[39­41] GSH­related genetic polymorphisms 
linked to various cancers (colo rectal can­
cer,[42] leukaemia,[43,44] lung cancer,[45,46] blad­
der can cer,[47] gastric cancer,[48,49] prostate 
cancer,[50­53] adult brain tumours,[54] basal cell 
carcinoma[55]) and linked to other disorders 
(autism,[12,13] hyper tension,[56,57] respiratory 
diseases,[58,59] cataract,[60] myelo dysplastic 
syndrome,[61,62] glioma[63] and male idio­
pathic infertility. [64]) There were 9 RCTs 
identified from two systematic reviews of 
the use of GSH to reduce chemotherapy­
induced toxicity (6 cisplatin, 2  axaliplatin, 
1 platinum); most suggested less toxicity in 
GSH groups. A systematic review of GSH as 
an adjuvant therapy in Parkinson’s disease 
identified one controlled trial[65] showing 
doubtful benefit. It was noteworthy that 
most studies did not report adverse events of 
GSH, and any reported were mild (Table 1).
Discussion
The idea of GSH­induced hypopigmenta­
tion may stem from early studies linking 
sulfhydral­containing compounds to the 
inhi bition of melanogenesis or from early 
anecdotal observations in Parkin son’s dis­
ease.  Proposed mechanisms of its action 
include inactivation of the melano genic 
enzyme, tyrosinase, influen cing the switch 
from eumelanin to phaeo melanin. [66,67] 
During melano genesis, tyrosinase is res­
ponsible for the con version of L­tyro sine 
to L­DOPA  and subse quently to dopa­
quinone, then the path way bifurcates to 
produce eumela nin or phaeomelanin. At 
a critical  point  in  the melanogenic path­
way  (asterisk,  Fig.  1),  thiols (cysteine and 
GSH) can react with L­dopaquinone to 
produce gluta thionyldopa, or act as a reser­
voir of L­cysteine by conjugating with L­dopa­
quinone to produce cysteinyl dopa. These two 
thioldopa substrates serve as a precursor to 
enhance the switch from eumelano genesis to 
phaeomelano genesis, resulting in lighter skin 
pigmentation.[68,69] This effect of GSH on skin 
pigmentation was reported half a century ago, 
with black human skin shown to exhibit lower 
levels of GSH than white skin.[70] In addition, 
GSH can act to lighten the skin directly 
through the quenching of free radicals and 
peroxides that have been shown to induce 
tyrosinase activity.[71] However, more evi­
dence is needed to prove this unequivocally.
GSH therefore has the potential to light­
en human skin. However, the only relia ble 
safety data on GSH are of sporadic use dur­
ing chemo therapy cycles, for a few weeks at 
most. There are no data on adverse effects 
of chronic high­dose GSH as used for skin 
lightening.
All chemotoxicity studies used injectable 
GSH. Reactive oxygen species are easily 
de com posed in aqueous solution; this  may 
explain the novelty of drug delivery as 
lozenges, which may be more stable 
(although two participants complained about 
the taste). The oral route reduces potential 
adverse events associated with intravenous 
(IV) administration but is associated with 
low bioavailability. Effective topical GSH[25] 
may be useful for dermatologists treating 
hyperpigmentation, but it is worth noting 
that GSH as a thiol interacts with metalloid 
complexes that render it ineffective. Patients 
should be advised to avoid using GSH with 
over­the­counter skin lightening creams that 
may contain mercury.[1]
All identified published trials report mild 
or no side­effects of GSH use. However, 
study duration was a maximum of 12 weeks. 
We identified one case series that reported 
intolerable adverse effects leading to discon­
tinuation of 5 mg oral GSH daily as adjuvant 
treatment for hepatocellular carcinoma 
(HCC). Seven of 8 patients died within 
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Fig. 1. GSH and its effect on skin lightening. Reactive oxygen species (ROS) have a direct activation effect 
on tyrosinase. Reduced GSH neutralises ROS formation and thus indirectly inhibits tyrosinase. At the 
dopachrome step* of the melanogenic pathway, interaction of thiols such as reduced GSH and cysteine 
bind with dopaquinone to produce thioldopas and favour phaeomelanogenesis. GST catalyses binding 
of GSH and dopaquinone. (DOPA = dihydroxyphenylalanine; DHI = dihydroxyindole; DHICA  = 
dihydroxyindole carboxylic acid.)
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1 year. However, the very severe prognosis associated with HCC was 
a likely confounder. [72] The effect of long­term administration of high 
doses of GSH on cells or organ systems remains unclear. Further­
more, since GSH causes a switch from eumelanin to phaeomelanin, 
it may increase UV photosensitivity, DNA damage and skin cancers 
in previously protected populations.[73] Of major concern are 
Table 1. Current list of human clinical trials associated with GSH
Reference
Country of origin
Study type
Indication
Subjects, n (sex), age
GSH dose and duration
Study duration Outcomes Adverse events
Skin whitening
 Hong et al.,[22] 
2005
Korea
Cases (uncontrolled)
Pharmacokinetic study
7 (male), 22 ­ 23 yr
65.5 (SD 4.5) kg, 50 mg 
GSH/kg body weight IV 
over 10 min, 10 d
IV GSH oxidised to GSSG (half­life = 
10 min)
Loading dose = 1.69 g/kg
Maintenance dose = 5.70 g/h/kg to 
reach extracellular concentration 
required to suppress intracellular ROS 
None reported
 Arjinpathana and 
Asawonda,[24] 2012
Bangkok, Thailand
RCT (double­blind, 
placebo)
Skin whitening
60 (18 male, 42 female), 
19 ­ 22 yr
250 mg capsules GSH twice 
daily, 4 wk
Significant reduction in melanin indices 
(UV spots) as measured by VISIA 
(Canfield Scientific Inc., USA) at all six sites 
in subjects who received GSH v. controls 
Flatulence
 Sriharsha et al.,[23] 
2015
India 
Pilot study
GSH soap: melanosis of 
the face
15, 15 ­ 70 yr
3 mo
Decreased hyperpigmentation in 11/15 
patients after 3 mo
None reported
 Watanabe et al.,[25] 
2014
Ibaraki, Japan
RCT (double­blind, placebo)
Skin whitening
30 (female), 30 ­ 50 yr
2% GSSG lotion twice daily, 
10 wk
Weeks 6 and 10:
Melanin index sign lower GSSG v. placebo
Keratin index sign lower GSSG v. placebo 
Mild erythema of 
the face (n=1)
 Handog et al.,[26] 
2015
Manilla, Phillipines
Single­arm trial (not 
blinded)
GSH­containing lozenges 
Skin whitening
30 (female), 22 ­ 42 yr 
500 mg daily, 8 wk
Decreased melanin index after 2 wk
All subjects showed a significant 
decrease in melanin index from baseline 
(p<0.0001)
Sore gums (n=1)
Undesirable 
flavour/texture of 
lozenge (n=1)
Chemotherapy drugs neuroprotection
 Cascinu et al.,[27] 
1995
Italy
RCT (double­blind, placebo)
Prevent cisplatin toxicity 
in gastric cancer 
50
GSH 1.5 g/m2 in 100 mL 
saline IV over 15 min
600 mg GSH IM, days 2 ­ 5
15 wk
Neuropathy 
Week 9: 0 GSH v. 16 placebo
Week 15: 4/24 GSH v. 16/18 placebo
None reported
 Colombo et al.,[28] 
1995
Italy
Random, phase II
Prevent cisplatin toxicity 
in relapsed ovarian cancer 
33
50 mg/m2 weekly ± 2.5 g/m2 
GSH, 9 wk
Higher (100% dose) cisplatin intensity 
was received by 56% GSH v. 27% 
control
None reported
 Parnis et al.,[29] 
1995
Australia
RCT (double­blind, 
placebo)
Prevent cisplatin toxicity 
in ovarian cancer
12
GSH 1.5 g/m2 over 15 min
CDDP 40 mg/m2 over 2 h for 
2, 3 or 4 consecutive days
NR
No significant protection None reported
 Bogliun et al.,[30] 
1992
Italy
Placebo controlled
Prevent cisplatin toxicity 
in ovarian cancer
33
CDDP total dose 500 ­ 675 
mg/m2 ± GSH 2.5 g/m2 IV 
over 15 min, 1 wk
Less severe neurotoxicity after 
co­treatment with all methods
Similar in both 
groups except 
oliguria greater in 
placebo group
 Smyth et al.,[31] 
1997
United Kingdom
RCT (double­blind, 
placebo)
Prevent cisplatin toxicity 
in ovarian cancer 
151 (female), 21 ­ 76 yr
6 cycles of 100 mg/m2 ± 3 g/
m2 + GSH IV over 15 min, 
3 wk
6 courses of cisplatin, 58% GSH v. 39% 
control 
Improved creatinine, GSH 74% v. 62% 
(p=0.006)
GSH improved depression, emesis, 
neurotoxicity, hair loss, shortness of breath 
None reported
Continued ...
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potentially severe complications (septicaemia, infective endocarditis 
and transmission of blood­borne infections) of IV administration of 
GSH by people with no health qualifications. Recent Food and Drug 
Administration warnings also point to a need for increased public 
awareness of potential harm.[74]
Conclusion
This brief review evaluates recent clinical studies on the use of GSH. 
Despite widespread use of IV GSH, no clinical report was identified. 
Large RCTs of long­enough duration and follow­up are warranted 
for the safe treatment of pigmentary disorders. The psychosocial 
impact of systemic skin lightening is a Pandora’s box best addressed 
by multidisciplinary teams including social scientists, psychologists 
and psychiatrists.
Source of funding. Funded by the South African Medical Research 
Council.
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RCT (double­blind, 
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None reported
Neurodegenerative disorders
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Parkinson’s disease
9
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None reported
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2009
USA
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Safety and preliminary 
efficacy in Parkinson’s 
disease 
21
1 400 mg GSH IV or 
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3 mo
Unified Parkinson’s Disease Rating Scale 
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group v. placebo
No adverse events 
due to GSH
 Mischley et al.,[38] 
2015
USA
Safety and tolerability 
of intranasal GSH in 
Parkinson’s disease 
30
600 mg/d of intranasal 
GSH v. placebo (saline) in 
3 divided daily doses
3 mo
All groups met tolerability criteria No adverse events 
due to GSH
NR = not reported; IM = intramuscular.
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